For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
The Canadian Cancer Trials Group is seeking nominations for the 2022 Recognition Awards honouring individuals who have contributed significantly to the mission and activities of the Group.
The 2022 Annual Spring Meeting of Participants is fast approaching!!
Meeting Information
The Panel on Research Ethics and the Secretariat on Responsible Conduct of Research are pleased to announce the release of TCPS 2: CORE-2022.
The Frances A Shepherd Award is awarded to investigators or post-graduate trainees, traveling to present CCTG related work at major international meetings where the material has been accepted for presentation. Each award will be approximately $1000 and offered twice a year. Applicants who have had their research accepted for oral or poster presentation at an international scientific meeting and have not received another award to support their travel are eligible to apply.
We are getting closer to the 2022 Virtual CCTG Annual Spring Meeting of Participants which will be held from April 28 - May 01, 2022!
Louise joined the CCTG Patient Representative Committee last year and is supporting the Melanoma & Quality of Life Committees. She is a married mother of five and Nana to 11 who enjoys spending time with her family, gardening and reading. Louise’s background is in Education and has participated as a Patient Partner in many groups and projects on both a National and Provincial level.
"I hope to improve the Patient experience and to encourage cancer patients to be involved in clinical trials and help foster change to improve the future of treatments," says Louise
The main purpose of this job is to provide electronic clinical database management from collection and entry to statistical analysis and reporting of data.
